A Phase I Pharmacokinetic Study of Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction.
Phase of Trial: Phase I
Latest Information Update: 30 Oct 2017
At a glance
- Drugs Belinostat (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- 26 Oct 2017 Status changed from recruiting to completed.
- 08 Mar 2017 Planned primary completion date changed from 4 Mar 2017 to 8 Jan 2018.
- 17 Feb 2016 Planned End Date changed from 1 Mar 2016 to 1 Mar 2018 as reported by ClinicalTrials.gov.